Scarica l'app Stockscreener
176.96
1.54%
2.69
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$174.27
Aprire:
$174.65
Volume 24 ore:
616.27K
Relative Volume:
0.57
Capitalizzazione di mercato:
$19.79B
Reddito:
$9.54B
Utile/perdita netta:
$841.00M
Rapporto P/E:
23.78
EPS:
7.44
Flusso di cassa netto:
$1.02B
1 W Prestazione:
+3.58%
1M Prestazione:
+2.59%
6M Prestazione:
+8.80%
1 anno Prestazione:
+17.93%
Intervallo 1D:
$174.58
$177.25
Intervallo di 1 settimana:
$170.53
$177.25
Portata 52W:
$146.17
$182.38
Quest Diagnostics Inc Stock (DGX) Company Profile
Nome
Quest Diagnostics Inc
Settore
Industria
Telefono
(973) 520-2700
Indirizzo
500 PLAZA DRIVE, SECAUCUS
Confronta DGX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
176.96 | 19.35B | 9.54B | 841.00M | 1.02B | 7.44 |
|
TMO
Thermo Fisher Scientific Inc
|
460.72 | 169.53B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
200.56 | 139.75B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
658.06 | 49.94B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
114.62 | 32.16B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
179.86 | 30.17B | 15.50B | 1.33B | 2.16B | 7.34 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-02 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
| 2025-01-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | Jefferies | Buy |
| 2024-10-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Ripresa | Evercore ISI | In-line |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2024-02-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-01-03 | Iniziato | Barclays | Equal Weight |
| 2023-12-12 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-06-29 | Iniziato | Piper Sandler | Neutral |
| 2023-05-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-03 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-23 | Iniziato | Evercore ISI | In-line |
| 2022-11-17 | Downgrade | Citigroup | Neutral → Sell |
| 2022-08-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-23 | Downgrade | UBS | Buy → Neutral |
| 2022-02-02 | Downgrade | Jefferies | Buy → Hold |
| 2022-01-28 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-03-12 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Aggiornamento | Argus | Hold → Buy |
| 2020-07-29 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-06-09 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-04-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Downgrade | Goldman | Neutral → Sell |
| 2019-04-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-03-18 | Ripresa | Credit Suisse | Neutral |
| 2019-01-31 | Downgrade | Argus | Buy → Hold |
| 2019-01-17 | Iniziato | UBS | Neutral |
| 2019-01-03 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Quest Diagnostics Inc Borsa (DGX) Ultime notizie
Major Clinical Trials Launch: New Blood Test Could Transform Post-Surgery Cancer Detection - Stock Titan
Quest Diagnostics (DGX) Insider Plans $968k Share Sale – Form 144 | SBS SEC FilingForm 6-K - Stock Titan
What to Expect From Quest Diagnostics' Q2 2025 Earnings Report - MSN
Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care - MarketScreener
How many analysts rate Quest Diagnostics Incorporated as a “Buy”Get exclusive market analysis for investors - Jammu Links News
What is Quest Diagnostics Incorporated company’s growth strategyTremendous gains - Jammu Links News
Quest Diagnostics Incorporated Stock Analysis and ForecastFree Predictions - Jammu Links News
What are the technical indicators suggesting about Quest Diagnostics IncorporatedMaximize your returns with expert insights - Jammu Links News
What catalysts could drive Quest Diagnostics Incorporated stock higher in 2025Turbocharged investment results - Jammu Links News
Quest Diagnostics Raises 2025 Guidance - AOL.com
Quest Diagnostics Insider Selling: A Signal of Caution or a Strategic Move Amid Strong Fundamentals? - AInvest
Published on: 2025-08-01 19:05:55 - metal.it
Is Quest Diagnostics Incorporated stock overvalued or undervaluedFinancial News Updates Backed By Experts - Jammu Links News
Earnings visualization tools for Quest Diagnostics IncorporatedVerified Signal From Chart Patterns Detected - metal.it
Drug Abuse Testing Market Forecast and Company Analysis - GlobeNewswire
Drug Abuse Testing Market Forecast and Company Analysis Report 2025-2033 Featuring Danaher, LabCorp, Abbott, Quest Diagnostics, Thermo Fisher Scientific, F. Hoffmann-La Roche, Bio-Rad, Medtronic - Yahoo Finance
Quest Diagnostics Breakthrough: New Long-Read DNA Test Revolutionizes Ataxia Movement Disorder Detection - Stock Titan
North America Autoimmune Disease Diagnostics Market Report - GlobeNewswire
North America Autoimmune Disease Diagnostics Market Report 2025-2033 Featuring Bio-Rad, Abbott, Roche, Quest Diagnostics, Thermo Fisher Scientific, BioMerieux, Myriad Genetics, Siemens Healthineers - Yahoo Finance
What makes Quest Diagnostics Incorporated stock price move sharplyTrade Setups With Clear Risk Limits Highlighted - metal.it
Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term - sharewise.com
What is the risk reward ratio of investing in Quest Diagnostics Incorporated stockInvest smarter with real-time trading alerts - jammulinksnews.com
Why is Quest Diagnostics Incorporated stock attracting strong analyst attentionMarket-beating performance - Jammu Links News
Published on: 2025-07-28 06:28:08 - jammulinksnews.com
Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Quest Diagnostics (NYSE:DGX) Stock Price - MarketBeat
What analysts say about Quest Diagnostics Incorporated stockDynamic growth stocks - PrintWeekIndia
How high can Quest Diagnostics Incorporated stock price go in 2025High-performance investment picks - jammulinksnews.com
Quest Diagnostics Trading Volume Drops 31.43% to $364 Million Ranking 317th Despite Stock Price Rise - AInvest
Options Corner: Quest Diagnostics' Post-Earnings Digestion Drama Opens A Science-Backed Opportunity - inkl
Quest Diagnostics’ revenue up 15.2% to USD 2.76B in Q2 2025 - Medical Buyer
Barclays Reaffirms Their Hold Rating on Quest Diagnostics (DGX) - The Globe and Mail
Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight - GuruFocus
Quest Diagnostics Incorporated's (NYSE:DGX) Shares May Have Run Too Fast Too Soon - 富途牛牛
Quest Diagnostics (DGX) Price Target Raised by UBS, Rating Maint - GuruFocus
U.S. DTC Wellness Testing Market Forecast to 2030: A $1.91 - GlobeNewswire
Quest Diagnostics (DGX) Price Target Raised by Deutsche Bank Ana - GuruFocus
Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025 - ADVFN Brasil
Quest Diagnostics Incorporated (NYSE:DGX) Q2 2025 Earnings Call Transcript - Insider Monkey
Quest Diagnostics (DGX) Price Target Raised by Deutsche Bank | D - GuruFocus
Is Quest Diagnostics Incorporated a good long term investmentConsistently exceptional gains - Autocar Professional
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MSN
Quest Diagnostics Inc (DGX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised ... - Yahoo Finance
Quest Diagnostics Inc (DGX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised ... By GuruFocus - Investing.com Canada
DGX Q2 Deep Dive: Acquisitions, Advanced Diagnostics, and Utilization Trends Drive Growth - TradingView
What drives Quest Diagnostics Incorporated stock priceBreakthrough financial growth - jammulinksnews.com
Quest Diagnostics Lifts Outlook As Testing Demand Grows - Finimize
Quest Diagnostics Surges to 241st in Daily Rankings with $476 Million Turnover - AInvest
Quest Diagnostics Inc Azioni (DGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
7.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):